Sakura Bio is an innovative biotech company aiming to transform the future of cell therapy with effective, durable, and accessible T and NK cell treatments.
Our core technology, T-Boost, reprograms T and NK cells during the manufacturing process to enhance potency, persistence, and resistance to the tumor microenvironment—addressing critical limitations of current CAR-T and other cell therapies.
T-Boost is a modular, plug-in solution that integrates easily into existing workflows and supports a wide range of modalities, including CAR-T, TCR-T, CAR-NK, TILs, and next-gen approaches for both solid and hematologic tumors.
Backed by strong preclinical data, T-Boost offers a scalable, platform-level opportunity to improve therapeutic outcomes and address major pain points in a fast-growing market.
Our T-boost-derived lead product, Skill-T (Super-Killer T cells), is an off-the-shelf, non-genetically modified allogeneic T-cell therapy.
Skill-T has demonstrated remarkable effectiveness in AML and solid tumors in various models, including mouse models for both AML and ovarian cancer, while maintaining a high safety profile with minimal risk of graft-versus-host disease (GvHD).
Company Details
- Employees
- 8
- Founded
- -
- Address
- Ramat Hasharon, Il
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.sakurabio.com
- Keywords
- strategic leadership.
- HQ
- Ramat HaSharon
Sakura Bio Questions
Sakura Bio's website is http://www.sakurabio.com
Sakura Bio's LinkedIn profile is https://il.linkedin.com/company/sakura-bio
Sakura Bio has
8 employees.
View email and phone details for 8
employees at Sakura Bio.
Sakura Bio's industry is
Biotechnology Research
Sakura Bio's top competitors are
Rambam Medtech,
Aspivix,
Point6 Bio,
Vlx Ventures,
Immunyx Pharma,
Protica Bio,
Everly Bio,
Identifai Genetics,
Planetech - Climate Change Technologies,
Ocon Therapeutics.
Sakura Bio's categories are Biotechnology Research
Sakura Bio's founding year is 2022
